Germantown, Md.-based Neuralstem is involved in a Phase 1 human clinical trial testing the safety and feasibility of using NSI-566 spinal cord-derived neural stem cells to repair chronic spinal cord injury.

A biopharmaceutical company, Neuralstem develops nervous system therapies derived from neural stem cell technology.

Here are six takeaways:

1. NSI-566 represents the company's lead stem cell therapy candidate.

2. University of California San Diego serves as the study site, and just added a new cohort of four patients.

3. The four new patients all have AIS-A complete, quadriplegic, cervical injuries involving C5-C7 cord.

4. The patients suffered the injury one to two years before undergoing stem cell treatment.

5. The treatment involves six injections of NSI-566 into the spinal cord's affected area.

6. UCSD researchers are analyzing long-term safety data from the study's first cohort on chronic complete thoracic injuries.

More articles on spine: Dr. Scott Blumenthal performs 1st US herniated disc surgery with Anchor Orthopaedics tissue kit 5 highlights Private practice in spine surgery: Key challenges & opportunities from Dr. Scott Blumenthal Cervical Spine Research Society names 5 new officers

View post:
UC San Diego adds 4 patients to Neuralstem's neural stem cell study for spinal cord injury: 6 takeaways - Becker's Orthopedic & Spine